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8th-9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
 Genetic
 Rare
 Autosomal recessive (majority)
 Portugal - 1/4000
 Almost 70!
9th November, 2018 
LYSOSOMAL STORAGE DISORDERS (LSDS)
 Chronic
 Progressive
 Large spectrum of severity 
& symptoms 
CNS pathology is a common hallmark of 
LSDs
LSDs are the commonest cause of 
paediatric neurodegenerative disease
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LYSOSOMAL STORAGE DISORDERS (LSDS)
 Chronic
 Progressive
 Large spectrum of severity 
& symptoms 
(from in utero/paediatric
to late adult onset forms)
 Pathophysiology
still unknown!
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 Progressive accumulation
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 Progressive accumulation
LYSOSOMAL STORAGE DISORDERS (LSDS)
?
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 1969
 Elizabeth Neufeld
THE ENZYME AS A DRUG?
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clathrin-mediated 
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Therapy
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PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Most frequent LSD
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
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PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Missing enzyme 
 isolated from human 
placentae
o IV injection into patients
o extraordinary results 
in blood tests!
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
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PROOF OF PRINCIPLE…
 Gaucher Disease (GD)
 Deficient enzyme: -glucocerebrosidase
 Gene: GBA (1q21)
 Intravenous injections of the 
recombinant enzyme
 Excellent results in systemic 
disease
Original illustration by Marcos Bernardino for  
Cristiana Petriz´s “Gigi e a Doença de Gaucher”, 2010
THE ENZYME AS A DRUG?
Pathology Available ERT
Gaucher Cerezyme® VPRIV®                                     Elelyso® 
(Imiglucerase; Genzyme) (Velaglucerase alfa; Shire) (Taliglucerase alfa; Pfizer)
Fabry Replagal® Fabrazyme®
(Agalsidase alfa; Shire) (Algalsidase beta; Genzyme)
MPS I Aldurazyme®
(Laronidase; Genzyme)
MPS II Elaprase®
(Idursulfase; Shire)
MPS IV A Vimizim®
(Elosulfase alfa; Biomarin)
MPS VI Naglazyme®
(Galsulfase; Biomarin)
Pompe Myozyme®
(Lumizyme, Alglucosidase alfa; Genzyme)
LAL 
deficiency
Kanuma®
(Sebelipase alfa; Alexion)
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 Several limitations
 Cost
 Lifelong dependance
 Ineffective for the CNS manifestations
…antibodies?
…secondary effects?
THE ENZYME AS A DRUG?
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Fabry
Mucopolysaccharidosis
type I
Sialidosis
Galactosialidosis
MPS IIIA
MPS IIIBKrabbe
Mucolipidosis
type II
Tay–Sachs
Metachromatic
leukodystrophy
Multiple sulfatase 
deficiency
Sandhoff
MPS IVA
MPS IVB
Fucosidosis
Alpha-
mannosidosis
Beta-mannosidosis
Pycnodysostosis
Danon
Wolman
Gaucher
Niemann-Pick
type C
Pompe MPS II
MPS IIIC
ML III
Farber
+ 70 diseases
most has no treatment! 
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STILL SO MUCH TO DO…
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STILL SO MUCH TO DO…
Fabry
Gaucher
Pompe
“With research,
possibilities are limitless”… 
9th November, 2018 
enzyme replacement therapies
more effective
able to cross the BBB
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 Final goal: brain
How?
intrathecal injection
(into the spinal canal/subarachnoid space so that it 
reaches the cerebrospinal fluid (CSF))
Clinical trials:
MPS I 
MPS II
MPS IIIA
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 Final goal: brain
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 Final goal: brain
How?
intracerebroventricular injections
Clinical trials:
MPS IIIB
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 Final goal: brain
How?
intracerebroventricular injections
intrathecal
Associated risks!
infections
cirurgical procedures
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 Final goal: brain
How?
Better vectors
Modified viruses (non-pathogenic)
retrovirusess (RNA)
adenoviruses (DNA)
lentiviruses
‘adeno-associated’  viruses(AAV)
9th November, 2018 
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 Final goal: brain
How?
Molecular ‘Trojan-horses’
+ signal-peptides
 ‘receptor-mediated transport’
insulin
apolipoprotein
…
9th November, 2018 
 ‘Broader’ approaches
i.e. 1 therapy  1 disease
(or  even more!)
 ‘Personalized’ approaches
i.e. 1 therapy for each mutation/
type of mutation
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 ‘Broader’ approaches
enzyme replacement therapies
more effective
able to cross the BBB
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 ‘Broader’ approaches
gene therapy
Clinical trials:
Metachromatic leukodystrophy
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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 ‘Broader’ approaches
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 ‘Broader’ approaches
Genetic substrate reduction
“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
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“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation               in particular
type of mutations 
How?
Molecular chaperones
stabilize mutant proteins
promote their transport into the lysosome
9th November, 2018 
AS POSSIBILIDADES (ILIMITADAS) DA
INVESTIGAÇÃO…
 ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation in particular
type of mutations
How?
Molecular chaperones
Galafold
TM
(Migalastat; Amicus Therapeutics)
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

“WITH RESEARCH, POSSIBILITIES ARE LIMITLESS”…
 ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation               in particular
type of mutations 
How?
 Correction of splicing mutations
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Our work at PT National Institute of Health…
 ‘Broader’ approaches
 gSRT for MPS
 ‘Personalized’ approaches
 correction of splicing mutations in different LSDs
Common denominator:
Genetic-based therapies
RNA-based
‘Easy’ to test at a cellular level – 1st stage
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THE FUTURE(S)…
gSRT +          enzyme replacement therapy
9th November, 2018 
gene therapy
THE FUTURE(S)…
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Personalized therapies
THE FUTURE(S)…
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